MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

AG-1478

CAS No. : 153436-53-4

MCE 国际站：AG-1478

产品活性：AG-1478 (Tyrphostin AG-1478) 是一种选择性的 EGFR 酪氨酸激酶抑制剂，IC₅₀ 为 3 nM。AG-1478 对 HCV 和脑心肌炎病毒 (EMCV) 具有抗病毒作用。

研究领域：JAK/STAT Signaling  |  Protein Tyrosine Kinase/RTK  |  Anti-infection

作用靶点：EGFR  |  HCV  |  Influenza Virus

In Vitro: AG-1478 (AG1478) is irreversible for growth regulation of human lung (A549) and prostate (DU145) cancer cell lines, cultured in chemically defined DMEM/F12 medium. AG-1478 seems to be more effective at lower concentrations, but is unable to completely inhibit growth of A549 cells. Inhibition of EGFR by specific tyrosine kinase inhibitor AG-1478 (AG1478) significantly decreases the angiotensin II-mediated synthesis of TGF-β and fibronectin by cardiac fibroblasts. EGFR is pharmacologically inhibited by small-molecule inhibitor AG-1478 with IC₅₀ of 4 nM. Both Polyfect (PF) and Superfect (SF) treatment lead to increased apoptosis in HEK 293 cells to a similar extent as assessed by flow cytometry. The antioxidant, tempol, significantly reduced dendrimer-mediated apoptosis for both PF and SF. AG-1478 (AG1478), at a 10-fold higher dose (100 μM) than used in signaling studies, is used as a positive control and significantly induced apoptosis in HEK 293 cells.

In Vivo: Administration of AG-1478 (AG1478) significantly reduces myocardial inflammation, fibrosis, apoptosis, and dysfunction in both two obese mouse models. ApoE^-/- mice are first fed with HFD for 8 weeks (ApoE-HFD), and then administrated with AG-1478 (10 mg/kg/day) or 542 (10 mg/kg/day) for another 8 weeks by oral gavage. AG-1478 or 542 treatment blocks HFD induced cardiac EGFR phosphorylation in vivo, without affecting the plasma level of low density lipoprotein (LDL) and total triglyceride (TG). Administration of EGF (10 nM) leads to a robust and reproducible elevation in EGFR phosphorylation that can be blocked by AG-1478 (AG1478), a known inhibitor of EGFR phosphorylation. Increasing doses of Polyfect (PF) result in a significant reduction in EGF-induced EGFR phosphorylation (p<0.05) but this is to a lesser extent than observed with AG1478.

相关产品：Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Immunology/Inflammation Compound Library  |  JAK/STAT Compound Library  |  Kinase Inhibitor Library  |  Protein Tyrosine Kinase Compound Library  |  Anti-Cancer Compound Library  |  Antiviral Compound Library  |  Differentiation Inducing Compound Library  |  Anti-diabetic Compound Library  |  Anti-Cardiovascular Disease Compound Library  |  Anti-Hepatitis C Virus Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Obesity Compound Library  |  Angiogenesis-Related Compound Library  |  Anti-Liver Cancer Compound Library   |  Anti-Colorectal Cancer Compound Library   |  Human Metabolite Library  |  Anti-Prostate Cancer Compound Library  |  Cancer Stem Cells Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Highly Selective Inhibitors Library  |  Ganoderic acid TR  |  Sofosbuvir impurity J  |  Alisporivir  |  EGFR/HER2/CDK9-IN-2  |  Lapatinib ditosylate  |  BMS-690514  |  Erlotinib-d₆ hydrochloride  |  PSI-7409 tetrasodium  |  Curcumin  |  EGFR/CDK2-IN-1  |  JBJ-04-125-02  |  Lactimidomycin  |  EGFR-IN-22  |  Cap-dependent endonuclease-IN-23  |  EGFR-IN-34  |  Epertinib  |  Ermanin  |  Dasabuvir  |  FNC-TP  |  DDX3-IN-1  |  Ponezumab  |  Hypericin  |  Antiviral agent 20  |  Monodes(N-carboxymethyl)valine Daclatasvir  |  NHC-triphosphate tetraammonium  |  Sofosbuvir-d₆  |  Trifluoperazine dihydrochloride  |  Grazoprevir potassium salt  |  1-Deoxymannojirimycin hydrochloride  |  Erlotinib Hydrochloride

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。